"Going global" is an important development strategy for Chinese biopharmaceutical companies to expand revenue, enhance competitiveness, and brand value. Chinese biopharmaceutical companies are heading towards the "deep sea" of internationalization. Through various methods such as overseas investment in factories, establishment of research and development institutions, technology transfer, international registration and certification, they are fully participating in global market competition and cooperation, integrating and optimizing resource allocation, and continuously improving their international innovation capabilities. How to grasp certainty in the wave of globalization, realize the grand vision of the internationalization strategy, seek new increments, is a major proposition in the current Chinese biopharmaceutical industry.
Frost & Sullivan (Frost & Sullivan, abbreviated as "Frost & Sullivan") is preparing to write the '2024 China Biopharmaceuticals Going Global: Current Situation and Trends Blue Book'. The aim is to track the process of Chinese biopharmaceuticals going global, sort out the driving factors for biopharmaceutical companies to accelerate their overseas layout, analyze markets in major developed countries and emerging countries abroad, and provide a platform for participating companies to showcase their strength and product advantages that have already gone global or are planning to go global. At the same time, the blue book will comprehensively and multi-dimensionally discuss and reflect on the development direction and value orientation of Chinese biopharmaceuticals going global, sharing relevant insights and analyses with industry stakeholders and investors. The release and exchange activities of the blue book will promote all parties in the market to deeply understand the overseas environment, development pattern, and market opportunities, and jointly draw an international development blueprint for China's biopharmaceutical industry with all parties.
The Life Sciences Practice of Frost & Sullivan cordially invites biopharmaceutical companies to participate in the Blue Book to jointly explore the development direction and prospects for China's biopharmaceutical industry going global.
Frost & Sullivan will officially release the 'Blue Book on the Current Situation and Trends of China's Biopharmaceuticals Going Global in 2024' at the '18th Frost & Sullivan China Growth, Innovation and Leadership Summit and 3rd New Investment Conference' from August 28th to 29th, 2024. The book will be simultaneously pushed in both Chinese and English on the Frost & Sullivan global official website and financial market media platforms worldwide. We look forward to the cooperation and support of relevant enterprises.
1
Research content
Analysis of the Background for Chinese Biopharmaceuticals Going Global:An overview of the current situation of China's biopharmaceutical industry, an analysis of internal and external driving factors for Chinese biopharmaceutical companies to go global, such as pressure from medical insurance negotiations and centralized procurement, significant improvement in China's biopharmaceutical R&D capabilities and quality, and potential overseas markets, has become an important strategic development path for Chinese biopharmaceutical companies;
The journey of Chinese biomedicine going global:Sort out the development process of Chinese biopharmaceuticals going global, from initial bulk drugs to generic drugs, and then to the globalization of innovative drugs. Analyze the characteristics, export scale, and representative events at different stages of going global, and depict a roadmap for Chinese biopharmaceuticals' overseas development;
Analysis of Major Overseas Markets:Select representative developed and emerging country markets for in-depth analysis, including the market's macroeconomic indicators, pharmaceutical market size, overview of the healthcare system, drug regulatory access systems, basic patient conditions, the main models and cases for Chinese pharmaceutical companies entering these markets, and the main challenges that Chinese pharmaceutical companies may face;
Importing bulk drugs into overseas markets:An in-depth analysis of the global industry pattern of bulk drugs, changes in China's bulk drug export scale, major export regions, main types of bulk drugs exported, and an analysis of the trend of bulk drugs going global, along with representative company cases;
Generic drug going global:Overview of the global generic drug market, analysis of the environment for Chinese generic drugs going global, summary of the current situation and advantages of Chinese generic drugs going global, outlook on future development trends of generic drug globalization, and display of representative cases of generic drug companies going global;
Emerging Drugs Going Global:Analyze the main strategies for Chinese innovative drugs to go global, explaining the applicability and advantages/disadvantages of various strategies through case studies; dissect the elements for Chinese innovative drugs to go global, including challenges, strategies and model selection, access and distribution policy environments in potential overseas markets, and the construction of professional teams overseas; analyze the current situation and trends of innovative drug exports, including the progress of overseas clinical trials, special qualification certifications from overseas regulatory authorities, License-out transactions and barrier analysis, and cases of innovative drugs approved for marketing overseas;
The '2024 China Biopharmaceuticals Going Global: Current Situation and Trends Blue Book' will include cooperative enterprises, presenting their business areas, pipeline layout, technology platforms, and differentiated advantages in the blue book, along with detailed company information descriptions and analyses. It will also showcase the development strategies of cooperative enterprises for going global, their overseas layout, practical achievements, and experiences, reflecting the global competitive advantages of cooperative enterprises and the core values of products that have gone global or are planning to go global.
2
Participation value
(1) Exploring Overseas Routes with Chinese Pharmaceutical Companies:Frost & Sullivan, based on a mature industry analysis model, covers the core elements of market analysis, demonstrates comprehensive and in-depth industry understanding, resonates with and provokes thought within the industry, connects to global expert networks and platform resources, joins hands with Chinese pharmaceutical companies to jointly explore ways to enhance value, and opens up a new chapter in overseas development;
(2) Enhance the global industry influence of enterprises and assist them in going global:The Blue Book will be released in both Chinese and English simultaneously on the Frost & Sullivan global official website, Frost & Sullivan official account, pharmaceutical vertical media, and major global financial media platforms. It will showcase the products that companies have already launched or plan to launch overseas, as well as their differentiated advantages. It will also enhance the visibility of companies in the capital market, improve their global recognition and influence, and assist the company's internationalization strategy.
(3) Global distribution to highlight the brand value of the company and reach potential overseas partners:The Blue Book will include typical international enterprise cases. Enterprises with existing products going global can leverage the Frost & Sullivan global media platform to deepen their promotional efforts and further enhance brand value globally. Enterprises planning to go global can showcase the highlights and strength of their technical products through the Blue Book to attract potential overseas partners or acquirers, thereby promoting the implementation of their global expansion;
(4) Build an overseas platform to showcase the advantages of our overseas services:The Blue Book can showcase the service content, service cases, and advantages of overseas service providers, providing reference information for enterprises that have successfully or plan to go global. It connects with the entire overseas supply chain and builds a platform for Chinese biopharmaceutical companies going global.
(5) Covering the capital market:Cover hundreds of millions of customers, seamlessly integrating media, funds, banking, and brokerage communication channels. With over 5,000 high-quality media resources, effective deployment and promotion strategies can be carried out with precise placement.
(6) Presenting the corporate image at overseas-related conferences:Share the overseas expansion models and strategies at online or offline events such as roundtable discussions, themed salons, and video live broadcasts on the internationalization theme organized by Frost & Sullivan.
3
Target cooperative enterprise type
(1) A B2B platform for biopharmaceutical companies planning to go global, providing a platform for product and strength display to accurately reach potential overseas partners;
(2) Biopharmaceutical companies that have successfully exported their products/technologies overseas should deepen their global brand influence and expand their overseas market footprint;
(3) Upstream and downstream service providers that provide services for biopharmaceutical companies going global, showcasing their service advantages, and building an industrial chain resource platform for biopharmaceutical companies that have already gone global or plan to do so.
4
For cooperation, please contact us.
Knowledge Center, Life Sciences Business Unit, Frost & Sullivan
Email: HCknowledgecenter@frostchina.com
Li Qian, Consulting Director of Life Sciences Business Unit, Frost & Sullivan Greater China Region
Email: qian.li@frostchina.com
Project Manager, Life Sciences Business Unit, Frost & Sullivan Greater China Region, Xu Chao
Email: xu.chao@frostchina.com
Recommended Reading
Biopharmaceutical manufacturing technology is entering its fourth wave, with CDMO service capabilities being upgraded once more to fully empower large-scale biopharmaceutical production.
[Global Release] Frost & Sullivan Assists in the Internationalization Strategy of Chuangjian Medical
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating a wealth of project experience across various sub-sectors of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry consulting, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
